Provided by Tiger Fintech (Singapore) Pte. Ltd.

Harmony Biosciences Holdings, Inc.

33.19
+0.0000
Post-market: 33.190.00000.00%19:05 EDT
Volume:536.00K
Turnover:17.69M
Market Cap:1.90B
PE:13.22
High:33.42
Open:32.70
Low:32.19
Close:33.19
Loading ...

Company Profile

Company Name:
Harmony Biosciences Holdings, Inc.
Exchange:
NASDAQ
Establishment Date:
2017
Employees:
268
Office Location:
630 West Germantown Pike,Suite 215,Plymouth Meeting,Pennsylvania,United States
Zip Code:
19462
Fax:
- -
Introduction:
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. It offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Directors

Name
Position
Jeffrey S. Aronin
Director, Chairman
John C. Jacobs
President and Chief Executive Officer, Director
Andreas Wicki
Director
Antonio Gracias
Director
Gary Sender
Director
Jack B. Nielsen
Director
Juan A. Sabater
Director

Shareholders

Name
Position
John C. Jacobs
President and Chief Executive Officer, Director
Susan L. Drexler
Chief Financial Officer
Andrew Serafin
Chief Business Officer
Jeffrey Dayno
Chief Medical Officer
Jeffrey Dierks
Chief Commercial Officer